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Over the last decade, the stem cell field has been one of the most fascinating 
areas of medical research. In several types of malignancy, both 
haematological and solid tumours, tissue stem cells are now implicated as 
cancer initiating cells. Chronic myeloid leukaemia (CML) is a paradigm cancer 
in this field. It is a clonal disorder of the haemopoietic stem cell (HSC) that 
affects 1 to 2 individuals per 100,000 every year and is associated with an 
increased production of mature and immature myeloid cells as a consequence 
of the formation of the Philadelphia chromosome (Ph) and Bcr-Abl oncogene.  
Extensive knowledge regarding the central role of Bcr-Abl in disease 
pathogenesis, acquired over many years, has facilitated development of new 
drugs that selectively target Ph+ malignant cells. In this article, we review the 
main characteristics of cancer stem cells and discuss novel therapeutic 
approaches that aim to eradicate CML stem cells.   
 
Stem cells are characterised by the capacity to divide and produce identical 
copies of themselves (self-renewal) and to differentiate into many other types 
of cell. They are present in several regions of the human body at every stage 
of development from embryo to adult. Because of their versatility, stem cells 
have been studied extensively with the purpose of repairing and/or replacing 
damaged human tissue in a variety of diseases and injuries, including 
Parkinson's disease, stroke and diabetes. 
Stem cells are usually divided into two different subgroups, pluripotent stem 
cells, which differentiate during embryonic development into cells of the 
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endoderm, ectoderm, and mesoderm (i.e. embryonic stem cells) and 
multipotent stem cells, which are lineage specific and include e.g. HSC, 
neuronal stem cells and hepatic stem cells (Reviewed in [47]).  
The HSC is one of the best-characterised stem cell systems [88]. Progeny 
derived from HSCs consist of oligopotent progenitors for lymphoid and 
myeloid cells. As with all stem cells, HSCs have the ability to self-renew 
indefinitely  and to generate the cells of our blood and immune system, such 
as white and red blood cells and platelets. In adults, HSCs are produced in 
the bone marrow and, under the right conditions, are induced to migrate out 
into the blood stream (mobilisation). The signals that trigger a stem cell to 
undergo differentiation, self-renewal or to mobilise in vivo are still unclear, 
however it has been shown in vitro that HSC undergo differentiation upon 
treatment with SCF, Flt3L, Tpo, and IL-3 [14, 27, 30, 32, 61, 70, 98], whereas 
Wnts, Notch, and Sonic hedgehog (Shh) promote HSC proliferation [2, 7, 53, 
93]. 
Cancer stem cells, which have been identified in many forms of leukaemia, 
are thought to be generated, either by mutation in a normal stem cell which 
already has the capacity for self-renewal, or in a progenitor cell [23, 44, 55] 
which then acquires self-renewal potential – thus  abnormal self-renewal is 
considered one of the most distinguishing hallmarks of cancer cells. Self-
renewing cancer stem cells give rise to all the malignant progeny in a tumour, 
and if not completely eradicated by chemotherapy, they establish a reservoir 
of drug-resistant cells responsible for relapse after a chemotherapy-induced 
remission. 
Biomarkers in CML 
CML is an excellent example of a leukaemia in which the initiating event for 
early chronic phase (CP) occurs within the normal HSC compartment, yet for 
progression to blast crisis (BC) further mutation within the progenitor 
compartment with acquisition of self-renewal potential has been proposed (16, 
19).  
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CML arises as a consequence of a rare mutational event within a single 
pluripotent HSC, resulting in a reciprocal translocation between the long arms 
of chromosomes 9 and 22, leading to the creation of the Ph [83]. Disease 
progression can be divided into 3 phases: (1) CP, characterised by an 
excessive production of differentiated but functionally immature granulocytes; 
(2) accelerated phase (AP) characterised by an increased number of primitive 
precursors in the bone marrow (BM) and/or peripheral blood (PB); (3) and BC, 
where there is a block to differentiation leading to accumulation of primitive 
blast cells and acquisition of additional chromosomal abnormalities [15].  
The creation of the Ph results in the expression of a constitutively active 
tyrosine kinase, (p210)-Bcr-Abl [26], an oncoprotein that shows greater 
tyrosine kinase activity than its wild-type counterpart, c-abl [60]. Forced over-
expression of Bcr–Abl causes cytokine independent survival and cell growth 
and protects HSC from apoptosis in response to either growth factor 
withdrawal or DNA damage [29, 67, 73].  Bcr-Abl activity is necessary to cause 
stem cells to transform both in vitro and in vivo, leading to the development of 
leukaemia [84]. As a tyrosine kinase, Bcr–Abl acts constitutively to activate 
multiple signal-transduction cascades involved in cell growth and 
differentiation. In particular, Bcr-Abl expression triggers a number of signalling 
pathways that positively affect stem cell turnover, alter cellular adhesion and 
block apoptosis. Bcr-Abl substrates include CRKL [72, 74], RAS [62], RAF 
[75], phosphatidylinositol-3 kinase (PI3K) [90], JUN kinase [79], MYC [85], and 
STAT [89].  
Conventionally treatment response in the clinic is determined using standard 
laboratory techniques including full blood count, cytogenetics for Ph in BM 
and fluorescence in situ hybridisation and Q-RT-PCR for Bcr-Abl levels in PB.  
In the setting of clinical trials this has been greatly extended to assess the 
ability of new drugs to block proliferation or induce cell death and to inhibit 
Bcr-Abl and its down-stream effectors.  These biomarkers include, for 
example, markers of proliferation (Ki67, BrdU) and apoptosis (active caspase-
3, annexin V, TMRE, TUNEL), Bcr-Abl phosphorylation, STAT 1, 3 and 5 
signalling and AKT phosphorylation, aiming to correlate individual or 
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combinations of biomarkers with plasma drug levels obtained at similar time-
points. More exploratory pharmacogenetic and pharmacogenomic 
assessments examine whether individual genetic variation relating to the 
target pathway for the drug of interest, or relating to overall drug metabolism, 
impact upon treatment response or predisposition to serious side effects. In 
certain instances more global tumour-related genomics, proteomics and 
metabonomics have been conducted, aiming to identify additional pathways 
altered by the drug of interest or associated with either response to therapy or 
disease progression despite therapy. One example of successful biomarker 
development utilised Western blotting for P-CRKL in total leucocytes derived 
from PB to determine imatinib mesylate (IM) sensitivity in vivo and showed a 
positive correlation between IM sensitivity and clinical response [97]. 
Our group has identified a subpopulation of deeply quiescent stem cells in all 
patients with CP CML. We have demonstrated that this quiescent 
subpopulation has a primitive phenotype (CD34+, CD38-, HLA DR-, CD45RA-, 
CD71-) and can induce Ph+/Bcr-abl+ reconstitution following transplantation in 
immunocompromised mice, suggesting that in vivo the quiescent state is only 
temporary and reversible under specific circumstances [40]. The presence of 
quiescent CML stem cells with self-renewal and transplantation capability may 
explain the historical failure of intensive cell cycle-dependent chemotherapy to 
eradicate CML, with subsequent relapse in all patients. Distinct from their 
normal counterparts, CML HSC are characterised by autocrine production of 
IL-3 and G-CSF and are therefore able to survive and proliferate in the 
absence of exogenous growth factors [45, 46]. Interestingly, autocrine IL-3 
production is switched on as quiescent cells move into cell cycle, suggesting a 
possible future target for therapy [41]. In terms of CML stem cell related 
biomarkers, the rarity of the target population makes all such studies 
challenging. However the activity of Bcr-Abl, before and after drug treatment 
in vitro or in vivo, can now be tracked in small cell samples using flow 
cytometry detection of p-CRKL [36].  
Targeted Therapeutics and New Research in CML 
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Recent advances in our understanding of stem cell molecular and cellular 
biology has enabled scientists to begin to explore their use in cell-based 
therapies and as tools in drug discovery. Over all tumour areas work with 
cancer stem cells is less advanced, however in the leukaemias stem cells are 
detectable in both BM and PB which are easily accessible.  An added 
advantage for CML is that the underlying molecular and cellular biology are 
reasonably well understood. In order to eradicate CML stem cells we need to 
identify relevant selective targets, which in turn, requires a comprehensive 
understanding of how and why cancer/CML stem cells differ from normal stem 
cells, including the factors that are important in triggering malignant 
transformation and disease progression. Our research is now focusing on 
understanding what controls maintenance of CML stem cell quiescence and 
the molecular effects induced by Bcr-Abl expression at the stem cell level. 
This review will discuss three different approaches recently used to selectively 
target CML stem cells: (1) targeting Bcr-Abl activity using Tyrosine Kinase 
Inhibitors (TKI); (2) combining growth factor stimulation to induce CML cell 
cycle re-entry with TKI; (3) targeting pathways downstream of Bcr-Abl, such 
as RAS (table 1). 
Targeting Bcr-Abl Activity Using TKIs 
 
The current first line therapy for patients with CP CML is IM (Gleevec or 
Glivec, Novartis Pharmaceuticals, Basel, Switzerland) [4], a compound 
belonging to the 2 phenylaminopyrimidine family.  IM is a rationally designed 
TKI of Abl, platelet-derived growth-factor receptor (PDGFR) α and β, and KIT 
[76]. Since the (p210)-Bcr-Abl tyrosine kinase originates from Abl, IM shows 
an impressive efficacy against proliferating Ph+/Bcr-Abl+ leukaemic cells [65]. 
The mechanism of action of IM was originally thought to be by acting as a 
competitive inhibitor of the ATP-binding pocket. Recently it has been shown 
that IM occupies only part of the ATP-binding pocket of the enzyme, and that 




IM induces a rapid haematological and cytogenetic response in the majority of 
CP CML patients (complete cytogenetic response 82% at 60 months) [25]. 
However, IM does not eliminate Bcr-Abl transcripts in the majority of patients, 
suggesting the persistence of minimal but detectable residual disease [8, 43]. 
A reservoir of resistant leukaemic stem cells is likely to explain this residual 
disease, as well as the rapid kinetics of relapse observed in most patients 
who discontinue IM, even a long time after achieving an apparent molecular 
remission [68] [66, 82]. The mechanism(s) through which these cells are 
inherently insensitive to IM, or become IM-resistant, remains unclear. One 
explanation may be the presence or generation of kinase domain mutations in 
the leukaemic stem cell compartment [34], however our group has been 
unable to detect such mutations following in vitro drug exposure and the rapid 
relapses following IM withdrawal in patients have shown wild type and not 
mutant Bcr-Abl. Our group and others have clearly demonstrated that CD34-
enriched CML stem cells are not targeted by IM, even at high concentrations, 
with the most primitive and quiescent cells most resistant to the drug [35, 40]. 
In addition, IM exerts a reversible anti-proliferative effect on these primitive 
quiescent CML cells, preventing their entry into cell cycle, thus making their 
targeting and eradication even more difficult [35, 39]. 
 
New TKIs with higher potency against wild type Bcr-Abl and with activity 
against the majority of IM-resistant mutants of Bcr-Abl have recently been 
developed and brought to the clinic. Two of these are nilotinib (formerly 
AMN107, Novartis) and dasatinib (formerly BMS-354825, Bristol-Myers 
Squibb). 
 
Nilotinib is a novel selective inhibitor of Bcr-Abl designed by modification to 
the molecular framework of IM, with activity based on the same mechanism of 
action: it binds to the inactive conformation of Abl, but with a better 
topographical fit. Pre-clinical data showed that in vitro nilotinib has significant 
activity against a number of IM-resistant Bcr-Abl mutants [33, 63]. In vivo, 
nilotinib promotes survival in IM-resistant CML mouse models and in mice that 
have been injected with Bcr-Abl-transformed cell lines or primary leukaemia 
cells [96]. A phase I clinical trial has recently shown that nilotinib induces 
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cytogenetic responses in 53% of patients with IM-resistant CML in CP [52]. 
Although nilotinib is more potent than IM, it is not effective against the T315I 
mutant [96].   
 
Dasatinib is an orally active multi-targeted Src- and Abl-kinase inhibitor that, 
differently from IM and nilotinib, binds to both the active and inactive 
conformation of the Abl kinase [58, 87]. Dasatinib is more effective than IM or 
nilotinib in the majority of cell lines expressing IM-resistant Bcr-Abl mutations, 
but not against those populations expressing the T315I mutation [96]. Despite 
the enhanced Bcr-Abl inhibitory activity, recent data from our lab showed that 
nilotinib and dasatinib, even at high concentrations, are ineffective against the 
quiescent CML stem cell population [21, 51]. Combination of the three Bcr-Abl 
TKIs may be more effective against IM-resistant subclones, as synergism of 
IM with nilotinib has been shown in cell lines and a murine model of CML [96]. 
As a consequence of disease persistence and resistance, TKIs cannot be 
considered a cure for the majority of patients with CML. If used in combination 
these drugs may be more effective against resistance mutations, however 
there is no evidence that this will increase their efficacy against the stem cell 
population. 
 
In the laboratory setting, mutation screens are commonly used to predict the 
profile of the mutations that confer TKI resistance in order to design a rational 
approach for combination strategies [3, 11, 19, 94, 95]. More than twenty-five 
amino acid substitutions at 21 positions have been identified so far to confer 
IM resistance in CML patients undergoing treatment [71]. Many of these 
mutations sterically preclude the TKI from binding to Bcr-Abl or cause a 
conformational change in the conserved phosphate binding (P) loop, 
diminishing drug binding [5, 12, 34, 37, 38]. 
 
Recently, mathematical models capable of describing the development and 
progression of tumours and their response to treatments have been proposed. 
These models provide quantitative understanding of the dynamics of 
tumourigenesis with respect to mutation, selection, genetic instability and 
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tissue architecture. The effects of IM on the autophosphorylation of Bcr-Abl 
and its downstream protein CRKL have been examined in CML cells using a 
mathematical model that predicted a minimal concentration for drug 
effectiveness [17]. More recently, a mathematical model has been used to 
analyse the in vivo kinetics of IM in CML patients [69]. The model indicates 
that IM is a potent inhibitor of the production of differentiated CML cells, but it 
does not totally eradicate CML. In addition, the model allows one to predict 
the probability of developing IM resistance mutations. Finally, a third 
mathematical model has proposed a selective functional effect of IM on 
proliferative leukaemia stem cells to explain Bcr-Abl transcript dynamics over 
time [80].  
 
Combining Growth Factor Stimulation with TKIs 
In vitro studies of AML and CML cells have previously shown that the 
effectiveness of cell cycle–specific chemotherapeutic agents can be enhanced 
by prior exposure to growth factors [6, 16, 92]. Furthermore, a clinical trial in 
AML confirmed improved responses for patients with standard risk disease 
who received growth factor priming [59]. Therefore, since TKIs are primarily 
targeting proliferating cells and IM is known to have anti-proliferative activity, 
an approach to eradicate primitive quiescent CML cells would be to induce 
them to re-enter the cell cycle before and after treatment with TKIs. Our group 
has recently shown that in vitro pulsing with growth factors, such as 
granulocyte-colony stimulating factor (G-CSF), promotes cell cycle re-entry 
prior to and following treatment with IM and significantly improves stem cell kill 
in comparison to IM alone [49]. G-CSF has already been used in order to 
overcome IM–induced neutropenia in patients with CML, leading to improved 
cytogenetic responses. Although assumed to be a consequence of increased 
exposure to IM, these improved responses could also represent a direct effect 
of G-CSF exposure on the progenitor compartment [50] [65, 78, 91]. The 
combination of IM and G-CSF has now been translated by our group into an 
NCRI clinical trial protocol named G-CSF and imatinib mesylate intermittently 
(GIMI). Results from this trial are expected 2008.  
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 Targeting Pathways Downstream of Bcr-Abl 
 
Recent advances in understanding the mechanisms of defective molecular 
pathways in cancer cells have enabled the identification of novel targets and 
therapeutic compounds. A new class of anti-cancer drugs that has recently 
been investigated is the farnesyl transferase inhibitors (FTIs). The FTIs 
competitively inhibit the enzyme farnesyl transferase (FT), irreversibly 
interrupting essential cell-signalling pathways. FTs act by coupling a 15-
carbon isoprenyl group to the target protein, allowing correct intracellular 
localisation and signal transduction [31, 54].  
 
FTIs were initially designed to inhibit prenylation of RAS. The RAS-MAP 
family is composed of protein-serine/threonine kinases that are highly 
conserved in evolution. These proteins are activated in response to a variety 
of growth factors and are known to regulate cell growth, death and 
differentiation [18]. Since RAS activation is implicated in leukaemogenic 
transformation by Bcr-Abl, inhibition of FT could be of therapeutic value in 
CML. Furthermore, mutations in the RAS family genes (H-RAS, K-RAS, and 
N-RAS) frequently occur in many types of cancer [10] and in haematological 
malignancies, suggesting wider application. However the observed anti-
tumour effects of FTIs are not solely due to RAS inhibition [7, 81], but  may 
involve inhibition of farnesylation of other proteins, including RhoB, RAC, 
centromere binding proteins and lamins [56] [1]. In fact malignancies 
containing non-mutated RAS may also be sensitive to FTIs, suggesting 
activity against an alternative pathway. For these reasons, the exact 
mechanism of action of FTIs in individual cancers is still unknown.  
 
FTIs tested in clinical trials include BMS-214662 (Bristol-Myers Squibb, 
Princeton, NJ,), L778123 (Merck & Co., Inc., Whitehouse Station, NJ,), 
tipifarnib (R115777; Zarnestra; Ortho Biotech Products, L.P., Bridgewater, 
NJ,), lonafarnib (SCH66336; Sarasar; Schering-Plough Corporation, 
Kenilworth, NJ,), FTI-277 (Calbiochem, EMD Biosciences, San Diego), and 
L744832 (Biomol International L.P., Plymouth Meeting, PA,) [13, 24]. 
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 BMS-214662 is a non-peptidomimetic cytotoxic FTI [64] that produces potent 
tumour regression and curative responses in human tumour xenografts and 
transgenic tumour models [28, 57]. BMS-214662 differs from other cytostatic 
FTIs, including lonafarnib and tipifarnib, which have non-curative activity 
against these tumours [28, 57]. BMS-214662 has been shown to preferentially 
kill non-proliferating cells (Proceedings of the AACR 42, 260S, 2001) and has 
anti-leukaemic activity in AML [22]. Our group has demonstrated that single 
agent BMS-214662 significantly reduces the quiescent CML HSC population 
in vitro, and is able to overcome the anti-proliferative accumulation that is 
seen with IM and dasatinib, if used in combination with these agents [20]. 
Although BMS-214662 exerts a strong FTI activity in vitro [81], its overall 
mechanism of action in killing the stem cell fraction is still not totally clear. 
 
Lonafarnib is a non-peptidomimetic FTI that showed activity against Bcr-Abl-
induced leukaemia in a murine model and against primary cells from patients 
with CML [42, 77]. In vitro, lonafarnib enhanced the toxicity of IM against K562 
and against the quiescent CD34+ cells [48], whereas a phase I clinical trial 
showed that, in CML patients in CP or AP resistant or intolerant to IM, 




CML is the first malignancy recognised to originate from a single clonal 
mutation. This abnormality leads to the formation of a population of CML stem 
cells known to be primitive, quiescent and cytokine independent. Allogeneic 
bone marrow transplantation is considered to be the only curative treatment 
for patients with CML. However, the restricted number of donors, advanced 
age of patients and toxicity of this approach limits its application. 
 
Although major advances in the treatment of CML have occurred in recent 
years with the development of IM, dasatinib and nilotinib, quiescent CML stem 
cells remain insensitive to these compounds, at least in vitro. Therefore, 
treatment strategies involving combination of TKIs or inhibitors of the Bcr–Abl 
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signal-transduction pathway are under intense investigation. Researchers are 
now focusing on drugs, such as FTIs, that specifically target quiescent stem 
cells. Remarkably, these drugs, alone or in combination with TKIs, have 
provided promising preliminary results in vitro (Figure 1). In particular BMS-
214662, by inducing selective apoptosis of quiescent leukaemic stem cells in 
CP CML, represents a useful tool for developing novel approaches to target 
cancer stem cells and for future drug discovery. 
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